In agreement with preclinical findings, in studies retrospectively evaluating SLFN11 status in samples of patients with ovarian cancer (mainly serous carcinoma) either by IHC or methylation-specific PCR, the proportion of samples with an SLFN11-negative (i.e., IHC 0+; H-score value 0–10) or methylated status counted consistently around 40% [12,25,49,52]. Here, SLFN11 is linked to serous adenocarcinoma.